Patent ID: 9649306
Date: 2017-05-16
CPC Classifications: A61K,A61P,C07B,C07D

Claim:
1. A method of treating a disease in a mammal, comprising administering to said mammal a therapeutically effective amount of an unsolvated crystalline form 2 of N-[5-(3,5-difluorobenzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide, wherein said crystalline form is characterized by an x-ray powder diffraction pattern comprising a peak at a 2-theta value of about 10.5±0.5 degrees, and wherein said disease is selected from the group consisting of non-small cell lung cancer (NSCLC), colorectal cancer (CRC), neuroblastoma, medulloblastoma and melanoma.